Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND -0.50%11 EV-to-EBIT is -0.59 as of Jul. 29, 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 381 Biotechnology companies, Vyome Holdings ranks worse than 262466.93% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vyome Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $7.61 Mil.
Vyome Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings EV-to-EBIT Related Terms
Vyome Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vyome Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's EV-to-EBIT falls into.
Vyome Holdings's current Enterprise Value is $6.49 Mil.
Vyome Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a EV-to-EBIT of -0.59 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vyome Holdings and its competitors. According to the industry distribution chart, Vyome Holdings ranks #999999 out of 381 companies in the Biotechnology industry.
Is Vyome Holdings' EV-to-EBIT too high?
Vyome Holdings' current EV-to-EBIT is -0.59. Based on the distribution chart, Vyome Holdings ranks #999999 out of 381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' EV-to-EBIT compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #999999 out of 381 companies for EV-to-EBIT. This places Vyome Holdings in the lower half of its industry. The industry median EV-to-EBIT is 12.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.81, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vyome Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vyome Holdings's current EV-to-EBIT is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current EV-to-EBIT of -0.59. The current EV-to-EBIT is -0.59. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vyome Holdings (HIND), the current EV-to-EBIT is -0.59 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
